Biological and genetic therapies for the treatment of Duchenne muscular dystrophy.

doi:10.1080/14712598.2022.2150543

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Biological and genetic therapies for the treatment of Duchenne muscular dystrophy.

Expert opinion on biological therapy - 1 Jan 2023

Wilton-Clark Harry, Yokota Toshifumi

Abstract excerpt

INTRODUCTION: Duchenne muscular dystrophy is a lethal genetic disease which currently has no cure, and poor standard treatment options largely focused on symptom relief. The development of multiple biological and genetic therapies is underway across various stages of clinical progress which could markedly affect how DMD patients are treated in the future. AREAS COVERED: The purpose of this review is to provide an...

Topics

Humans
Muscular Dystrophy, Duchenne
Dystrophin
Utrophin
Genetic Therapy
Mutation

Source

Open in PubMed

Identifiers

PMID: 36409820
DOI: 10.1080/14712598.2022.2150543

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics